ライフサイエンスコーパス: epoxyeicosatrienoic acid

1 ase in the cardioprotective eicosanoid 14,15-epoxyeicosatrienoic acid.

2 ive in the metabolism of arachidonic acid to epoxyeicosatrienoic acids.

3 ic acid to hydroxyeicosatetraenoic acids and epoxyeicosatrienoic acids.

4 arachidonic acid, to physiologically active epoxyeicosatrienoic acids.

5 N1 and CYP2N2 metabolize arachidonic acid to epoxyeicosatrienoic acids.

6 ncluding nitric oxide, prostacyclin, and the epoxyeicosatrienoic acids.

7 logically active hydroxyeicosatetraenoic and epoxyeicosatrienoic acids.

8 2+ channels, cytosolic phospholipase A2, and epoxyeicosatrienoic acids.

9 e P450 epoxygenase, the synthetic enzyme for epoxyeicosatrienoic acids.

10 um-derived arachidonic acid metabolite 11,12 epoxyeicosatrienoic acid (11,12 EET) (300 nmol/L).

11 Because the AA metabolite 11,12-epoxyeicosatrienoic acid (11,12-EET) can inhibit the epi

12 f CYP2C23 but not CYP2J2 and increased 11,12-epoxyeicosatrienoic acid (11,12-EET) levels in isolated

13 action was enhanced by the addition of 11,12-epoxyeicosatrienoic acid (11,12-EET), a cytochrome P450-

14 peak, containing both the 11-hydroxy-14, 15-epoxyeicosatrienoic acid (11-H-14,15-EETA) and 15-H-11,1

15 We have previously reported that 14,15-epoxyeicosatrienoic acid (14, 15-EET) is a potent mitoge

16 poxygenase arachidonic acid metabolite 14,15-epoxyeicosatrienoic acid (14,15-EET) inhibits apoptosis

17 chidonic acid preferentially generates 14,15-epoxyeicosatrienoic acid (14,15-EET), a metabolite known

18 nd the molecular mechanisms underlying 14,15-epoxyeicosatrienoic acid (14,15-EET)-induced angiogenesi

19 yme system metabolizes arachidonate to 14,15-epoxyeicosatrienoic acid (14,15-EET).

20 d by the epithelial-derived eicosanoid 14,15-epoxyeicosatrienoic acid (14,15-EET).

21 proposed unstable precursor 15-hydroxy-11,12-epoxyeicosatrienoic acid (15-H-11,12-EETA).

22 5,6-Epoxyeicosatrienoic acid (5,6-EET), a proposed CIF gener

23 n was highly enantioselective for (14R, 15S)-epoxyeicosatrienoic acid (76% optical purity).

24 0 mV) in rat myocytes were inhibited by 8, 9-epoxyeicosatrienoic acid (8,9-EET) in a dose-dependent m

25 ydroxyeicosatetraenoic acid and 14(S), 15(R)-epoxyeicosatrienoic acid (80 and 20% of total products,

26 poxidizes arachidonic acid to 11,12- and 8,9-epoxyeicosatrienoic acids (80 and 20% of total metabolit

27 tive arachidonic acid epoxygenase ((14S,15R)-epoxyeicosatrienoic acid, 99% of total products).

28 We present evidence in astrocytes that 5,6-epoxyeicosatrienoic acid, a cytochrome P450 epoxygenase

29 nduced soluble epoxide hydrolase inhibition, epoxyeicosatrienoic acid accumulation, and increased pul

30 The epoxyeicosatrienoic acid also restored the amplitude of

31 Moreover, 5,6-epoxyeicosatrienoic acid and 14,15-epoxyeicosatrienoic a

32 he osmotransducing cytosolic messenger 5'-6'-epoxyeicosatrienoic acid and allowed channel activation

33 arachidonic acid to 14,15-, 11,12-, and 8, 9-epoxyeicosatrienoic acids and 11- and 15-hydroxyeicosate

34 arachidonic acid to 14,15-, 11,12-, and 8, 9-epoxyeicosatrienoic acids and 19-hydroxyeicosatetraenoic

35 rachidonic acid into 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acids and 20-hydroxyeicosatetraenoic

36 These results designate epoxyeicosatrienoic acids and EDPs as unique endogenous

37 that metabolize arachidonic acid to produce epoxyeicosatrienoic acids and exert pleiotropic protecti

38 he cytochrome P450 (cP450) pathway producing epoxyeicosatrienoic acids and hydroxyeicosatetraenoic ac

39 The role of epoxyeicosatrienoic acids and NO was assessed with the b

40 CYP4A3 metabolizes arachidonic acid to both epoxyeicosatrienoic acids and vasoconstrictive 19,20-hyd

41 2J4 convert arachidonic acid to vasodilative epoxyeicosatrienoic acids, and CYP4A3 metabolizes arachi

42 ctive products, including PGs, leukotrienes, epoxyeicosatrienoic acids, and hydroxyeicosatetraenoic a

43 Epoxyeicosatrienoic acids are endogenous constituents of

44 ubules and collecting ducts, sites where the epoxyeicosatrienoic acids are known to modulate fluid/el

45 The epoxyeicosatrienoic acids are synthesized from arachidon

46 Epoxyeicosatrienoic acids are vasodilators with anti-inf

47 id epoxygenases and that CYP2J products, the epoxyeicosatrienoic acids, are endogenous constituents o

48 Arachidonic acid-derived epoxides, epoxyeicosatrienoic acids, are important regulators of v

49 The epoxygenase products, the epoxyeicosatrienoic acids, are pro-angiogenic, and down-

50 xide, trans-diphenylpropene oxide, and 14,15-epoxyeicosatrienoic acid as substrates.

51 THETAs join prostacyclin, nitric oxide, and epoxyeicosatrienoic acids as new members of the family o

52 -dependent metabolism of arachidonic acid to epoxyeicosatrienoic acids as the principal reaction prod

53 -phorbol-12,13-didecanoate and 5,6- or 14,15-epoxyeicosatrienoic acid, as well as thapsigargin, a kno

54 unts of arachidonic, eicosapentaenoic or 8,9-epoxyeicosatrienoic acids, but some uptake persisted eve

55 in epoxidation to all four regioisomeric cis-epoxyeicosatrienoic acids (catalytic turnover 65 pmol of

56 These results show that an impaired role of epoxyeicosatrienoic acids contributes, together with an

57 Arachidonic acid-derived epoxyeicosatrienoic acids could alleviate the systemic h

58 ts (+/-)-8,9-, (+/-)-11,12-, and (+/-)-14,15-epoxyeicosatrienoic acid (EET) (total turnover of approx

59 We developed novel orally active epoxyeicosatrienoic acid (EET) analogs and investigated

60 synthesis of the ethyl esters of both 11,12-epoxyeicosatrienoic acid (EET) and 11S,12S-dihydroxyeico

61 nase (CYP)-derived epoxygenated fatty acids, epoxyeicosatrienoic acid (EET) and epoxydocosapentaenoic

62 of Ca2+ pools were compared; 8,9- and 11,12-epoxyeicosatrienoic acid (EET) at 1.5 microM were comple

63 Diabetes is associated with decreased epoxyeicosatrienoic acid (EET) bioavailability and incre

64 on in cytochrome P450 2C11 (CYP2C11)-derived epoxyeicosatrienoic acid (EET) bioavailability.

65 In cirrhosis, 11,12-epoxyeicosatrienoic acid (EET) induces mesenteric arteri

66 r the kidney Cyp2c44 epoxygenase and for its epoxyeicosatrienoic acid (EET) metabolites in the in viv

67 cytochrome P450 epoxygenase Cyp2c44, a major epoxyeicosatrienoic acid (EET) producing enzyme in mice,

68 s), exogenous AA induced significant 14S,15R-epoxyeicosatrienoic acid (EET) production (241.82 ng/10(

69 epoxygenases convert arachidonic acid into 4 epoxyeicosatrienoic acid (EET) regioisomers, which were

70 hibition prevents hydrolysis of the enzymes' epoxyeicosatrienoic acid (EET) substrates, so they accum

71 e hydrolase (sEH) converts anti-inflammatory epoxyeicosatrienoic acid (EET) to dihydroxyeicosatrienoi

72 tography; and the results showed that 11,12- epoxyeicosatrienoic acid (EET) was the major product met

73 The CYP2J2 metabolites, 5,6-epoxyeicosatrienoic acid (EET), 14,15-EET, and the corre

74 ibition is likely a result of an increase in epoxyeicosatrienoic acid (EET)-mediated generation of RO

75 ytochrome P450 epoxygenase Cyp2c44, a murine epoxyeicosatrienoic acid (EET)-producing enzyme, promote

76 Epoxyeicosatrienoic acids (EET) and related epoxy fatty

77 hat targeting the formation of proangiogenic epoxyeicosatrienoic acids (EET) by the cytochrome P450 a

78 The eicosanoid epoxyeicosatrienoic acids (EET) from arachidonic acid wa

79 Epoxyeicosatrienoic acids (EET) have antihypertensive an

80 during cirrhosis, focusing on the actions of epoxyeicosatrienoic acids (EET), known to be potent regu

81 xamined the preglomerular actions of various epoxyeicosatrienoic acids (EET).

82 aenoic acid, and leukotriene B4), TRPV4 (5,6-epoxyeicosatrienoic acid [EET] and 8,9-EET), and TRPA1 (

83 -derived metabolites of arachidonic acid the epoxyeicosatrienoic acids (EETs) and hydrogen peroxide (

84 tes biologically active compounds, including epoxyeicosatrienoic acids (EETs) and hydroxyeicosatetrae

85 Epoxyeicosatrienoic acids (EETs) and other epoxy fatty a

86 ncubation with 17 mm glucose increased media epoxyeicosatrienoic acids (EETs) and reduced cell membra

87 ABPs (FABP3, FABP5, and FABP7) interact with epoxyeicosatrienoic acids (EETs) and the peroxisome prol

88 cis-Epoxyeicosatrienoic acids (EETs) and their hydrolysis pr

89 idonic acid to 5,6-, 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acids (EETs) and to 19- and 20-hydro

90 In bovine coronary arteries, epoxyeicosatrienoic acids (EETs) appear to function as E

91 Epoxyeicosatrienoic acids (EETs) are anti-inflammatory m

92 Epoxyeicosatrienoic acids (EETs) are cytochrome P450-epo

93 Epoxyeicosatrienoic acids (EETs) are endothelium-derived

94 Increasing endogenous levels of epoxyeicosatrienoic acids (EETs) are known for their ana

95 Epoxyeicosatrienoic acids (EETs) are major products of c

96 Epoxyeicosatrienoic acids (EETs) are potent endothelium-

97 Epoxyeicosatrienoic acids (EETs) are potent regulators o

98 Epoxyeicosatrienoic acids (EETs) are potent vasodilators

99 rachidonic acid epoxygenase metabolites, the epoxyeicosatrienoic acids (EETs) are powerful, nonregios

100 Epoxyeicosatrienoic acids (EETs) are products of cytochr

101 The epoxyeicosatrienoic acids (EETs) are products of cytochr

102 The epoxyeicosatrienoic acids (EETs) are products of cytochr

103 Epoxyeicosatrienoic acids (EETs) are small molecules pro

104 Epoxyeicosatrienoic acids (EETs) are synthesized by cyto

105 m to conduct a chemical screen, and identify epoxyeicosatrienoic acids (EETs) as a family of lipids t

106 However, AA is also converted to natural epoxyeicosatrienoic acids (EETs) by cytochrome P450 enzy

107 coronary arteries through its metabolism to epoxyeicosatrienoic acids (EETs) by cytochrome P450, we

108 CYP) epoxygenases CYP2C8 and CYP2J2 generate epoxyeicosatrienoic acids (EETs) from arachidonic acid.

109 ed from the cyclooxygenase (COX) pathway and epoxyeicosatrienoic acids (EETs) from the cytochrome P45

110 Epoxyeicosatrienoic acids (EETs) generated from arachido

111 Epoxyeicosatrienoic acids (EETs) have demonstrated antii

112 Epoxyeicosatrienoic acids (EETs) have potent antiinflamm

113 The cytochrome P450-derived epoxyeicosatrienoic acids (EETs) have potent effects on

114 Each of the four regioisomers of epoxyeicosatrienoic acids (EETs) is a candidate for bein

115 he chiral analysis of the four regioisomeric epoxyeicosatrienoic acids (EETs) is described.

116 of the CYP2B19 metabolites 11,12- and 14,15-epoxyeicosatrienoic acids (EETs) on keratinocyte transgl

117 Cytochrome P-450 (CYP)-derived epoxyeicosatrienoic acids (EETs) possess potent anti-inf

118 CYP2C50 and CYP2C54 metabolize AA to epoxyeicosatrienoic acids (EETs) primarily, and linoleic

119 Specifically, epoxyeicosatrienoic acids (EETs) produced from the P450

120 Renal cytochrome P450 (CYP)-derived epoxyeicosatrienoic acids (EETs) regulate sodium transpo

121 Endothelium-derived epoxyeicosatrienoic acids (EETs) relax vascular smooth m

122 This study addressed the hypothesis that epoxyeicosatrienoic acids (EETs) synthesized by CYP450 a

123 eans to enhance the biological activities of epoxyeicosatrienoic acids (EETs) to treat cardiac hypert

124 ochromes P450 metabolize arachidonic acid to epoxyeicosatrienoic acids (EETs) which have numerous eff

125 TEs), hydroxyeicosatetraenoic acids (HETEs), epoxyeicosatrienoic acids (EETs), and dihydroxyeicosatri

126 As), including arachidonic acid (AA)-derived epoxyeicosatrienoic acids (EETs), are endogenously produ

127 ovascular endothelial cells, total levels of epoxyeicosatrienoic acids (EETs), but not epoxydocosapen

128 activation of KCa channels, and whether the epoxyeicosatrienoic acids (EETs), derived via cytochrome

129 zes lipid signaling molecules, including the epoxyeicosatrienoic acids (EETs), epoxidized lipids prod

130 are metabolites of arachidonic acid (AA) and epoxyeicosatrienoic acids (EETs), have been identified a

131 rachidonic acid epoxygenase metabolites, the epoxyeicosatrienoic acids (EETs), in ENaC activity have

132 5,6-, 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acids (EETs), in inducing angiogenes

133 Epoxyeicosatrienoic acids (EETs), lipid mediators produc

134 nt in the kidney where its products, the cis-epoxyeicosatrienoic acids (EETs), modulate sodium transp

135 chrome P450 metabolites of arachidonic acid, epoxyeicosatrienoic acids (EETs), potently activate card

136 Epoxyeicosatrienoic acids (EETs), products of the cytoch

137 In this study, we investigated whether epoxyeicosatrienoic acids (EETs), the catalytic products

138 We have reported that epoxyeicosatrienoic acids (EETs), the cytochrome P450 (C

139 We have previously reported that epoxyeicosatrienoic acids (EETs), the cytochrome P450 ep

140 unds including 5,6-, 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acids (EETs), their corresponding di

141 unds including 5,6-, 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acids (EETs), their corresponding di

142 n the metabolism of arachidonic acid (AA) to epoxyeicosatrienoic acids (EETs), which affect multiple

143 We examined the effects of epoxyeicosatrienoic acids (EETs), which are cytochrome P

144 It serves to inactivate epoxyeicosatrienoic acids (EETs), which are generated in

145 The epoxyeicosatrienoic acids (EETs), which are products of

146 ses that promote the synthesis of protective epoxyeicosatrienoic acids (EETs).

147 levels of anti-inflammatory molecules called epoxyeicosatrienoic acids (EETs).

148 significantly attenuated in the presence of epoxyeicosatrienoic acids (EETs).

149 sible for the metabolism and inactivation of epoxyeicosatrienoic acids (EETs).

150 e in the biosynthesis of eicosanoids such as epoxyeicosatrienoic acids (EETs).

151 onic acid-derived eicosanoids referred to as epoxyeicosatrienoic acids (EETs).

152 zed by cytochrome P-450 epoxygenases to four epoxyeicosatrienoic acids (EETs): 14,15-, 11,12-, 8,9-,

153 ids, including 5,6-, 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acids (EETs); 5-, 8-, 9-, 12-, and 1

154 t in heart and active in the biosynthesis of epoxyeicosatrienoic acids (EETs); however, the functiona

155 lial metabolism (-35%, p < 0.01), vasoactive epoxyeicosatrienoic acids (EETs; -60%, p < 0.001) synthe

156 flammatory P-450 eicosanoid metabolites (cis-epoxyeicosatrienoic acids [EETs]) in the lung.

157 ality of CYP2J2 products matched that of the epoxyeicosatrienoic acid enantiomers present, in vivo, i

158 14(S),15(R)-, 11(R), 12(S)-, and 8(S),9(R)- epoxyeicosatrienoic acid enantiomers.

159 port that the 5,6-epoxide of anandamide, 5,6-epoxyeicosatrienoic acid ethanolamide (5,6-EET-EA), is a

160 droxyeicosatetraenoic acid ethanolamides and epoxyeicosatrienoic acid ethanolamides.

161 contrast, the parental arachidonic acid and epoxyeicosatrienoic acids failed to activate CB1 or CB2

162 revealed that 20-hydroxyeicosatetraenoic and epoxyeicosatrienoic acids formed by these pathways have

163 ti-inflammatory epoxy fatty acids, including epoxyeicosatrienoic acids from arachidonic acid to the c

164 as inhibition of adenosine-A2a receptors and epoxyeicosatrienoic acids had minimal effect.

165 Regio- and stereoisomeric epoxyeicosatrienoic acids have potent vasodilatory prope

166 pe channel) and to the osmotransducing lipid epoxyeicosatrienoic acid in heterologous expression stud

167 menting, for the first time, the presence of epoxyeicosatrienoic acids in human jejunum by gas chroma

168 In light of the well documented effects of epoxyeicosatrienoic acids in modulating renal tubular tr

169 was suggested by documenting the presence of epoxyeicosatrienoic acids in the human heart using gas c

170 Soluble epoxide hydrolase metabolizes epoxyeicosatrienoic acids in the vasculature and regulat

171 lites derived from omega-6 arachidonic acid, epoxyeicosatrienoic acids, increase angiogenesis and tum

172 Furthermore, local plasma epoxyeicosatrienoic acids increased during heating in co

173 ups after the Ca2+ ionophore A23187 or 14,15-epoxyeicosatrienoic acid, independent of store depletion

174 Nano- to picomolar 5, 6-epoxyeicosatrienoic acid induced [Ca2+]i elevation consi

175 hydrolase (sEH) catalyzes the conversion of epoxyeicosatrienoic acids into less active eicosanoids,

176 the cytochrome P450 epoxygenase product 5,6-epoxyeicosatrienoic acid is primarily responsible for hy

177 We have previously shown that 5, 6-epoxyeicosatrienoic acid is synthesized and released by

178 r variants in the genes that alter levels of epoxyeicosatrienoic acids is less convincing.

179 Furthermore, EET/dihydroxy-epoxyeicosatrienoic acid isomer ratios were elevated in

180 e can result in an increase in the levels of epoxyeicosatrienoic acids, leading to the attenuation of

181 (sEH) inhibitors, which increase endogenous epoxyeicosatrienoic acid levels, exhibit potent anti-inf

182 In summary, our results suggest that 5,6-epoxyeicosatrienoic acid may be a component of calcium i

183 id pools in rat heart myocytes and (b) 11,12-epoxyeicosatrienoic acid may play an important functiona

184 smooth muscle and endothelium suggests that epoxyeicosatrienoic acids may also be involved in the mo

185 achidonic acid pools in human heart and that epoxyeicosatrienoic acids may, therefore, play important

186 SFZ further stimulated the production of non-epoxyeicosatrienoic acid metabolites, suggesting a metab

187 membrane phospholipids and production of non-epoxyeicosatrienoic acid metabolites.

188 In addition, cis-epoxyeicosatrienoic acid mimics the growth-suppressive a

189 ional and biological approaches, the role of epoxyeicosatrienoic acids, nitric oxide (NO)/reactive ox

190 Importantly, neither 14,15-epoxyeicosatrienoic acid nor 19-hydroxyeicosatetraenoic

191 Extracellular administration of 11, 12-epoxyeicosatrienoic acid, one of the P450-mediated metab

192 ctive with preferential formation of (8R,9S)-epoxyeicosatrienoic acid (optical purities are 91 and 90

193 2N1 and CYP2N2, respectively) and (11R, 12S)-epoxyeicosatrienoic acid (optical purities are 92 and 70

194 y, such as hydroxyeicosatetraenoic acids and epoxyeicosatrienoic acids, play novel roles in glomerula

195 complex molecular mechanisms, with zinc and epoxyeicosatrienoic acids playing key roles.

196 Antagonizing NMDA-receptors or epoxyeicosatrienoic acid production reduces only the lat

197 The epoxyeicosatrienoic acids, products of the kidney P-450

198 city of the biological effect for the 11, 12-epoxyeicosatrienoic acid regioisomer.

199 ular tone by K(+)(Ca) channel activation and epoxyeicosatrienoic acid release and that endothelium-de

200 of K(+)(Ca) channels is only partly through epoxyeicosatrienoic acid release, indicating the presenc

201 lead to an increase in circulating levels of epoxyeicosatrienoic acids, resulting in the potentiation

202 rtholog of human CYP2J2) resulted in reduced epoxyeicosatrienoic acid synthesis.

203 used to inhibit cytochrome P450 2C9-mediated epoxyeicosatrienoic acid synthesis.

204 ted by blockade of the two critical steps in epoxyeicosatrienoic acid synthesis: release of arachidon

205 nic acid generates a series of regioisomeric epoxyeicosatrienoic acids that can be further metabolize

206 over, 5,6-epoxyeicosatrienoic acid and 14,15-epoxyeicosatrienoic acid, the cytochrome P450-dependent

207 Vitreous also contained CYP-derived epoxyeicosatrienoic acids; their levels were higher in n

208 onversion of the protective eicosanoid 14,15-epoxyeicosatrienoic acid to 14,15-dihydroxyeicosatrienoi

209 The addition of 5 microM 11, 12-epoxyeicosatrienoic acid to the perfusate prior to globa

210 poxide hydrolase catalyzes the hydrolysis of epoxyeicosatrienoic acids to dihydroxyeicosatrienoic aci

211 Soluble epoxide hydrolase converts epoxyeicosatrienoic acids to their corresponding diols,

212 ated a significantly increased production of epoxyeicosatrienoic acids, vasodilator metabolites of CY

213 When 5,6-epoxyeicosatrienoic acid was applied to the rat brain su

214 Endogenous epoxyeicosatrienoic acids were detected in both human an

215 They generate epoxyeicosatrienoic acids, which are known to have anti-

216 the epoxidation of arachidonic acid to form epoxyeicosatrienoic acids, which modulate bronchial smoo

217 cluding bioactivation of arachidonic acid to epoxyeicosatrienoic acids, which, in turn, have been imp

218 Epoxyeicosatrienoic acids with anti-inflammatory effects

219 osing actions of hydroxyeicosatetraenoic and epoxyeicosatrienoic acids within the vasculature.

220 d to measure vasoconstriction in response to epoxyeicosatrienoic acid, zinc, soluble epoxide hydrolas